Drug · CHEMBL963
OXYMORPHONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. OXYMORPHONE. Drugs and targets, record CHEMBL963. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL963
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 14-hydroxydihydromorphinone, 7,8-dihydro-14-hydroxymorphinone, Dihydroxymorphinone, IDS-NO-003, NIH 10323, NSC-19045, Oximorfona, Oxycodone hydrochloride impurity, oxymorphone-, Oxymorphone cii
- ChEMBL
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| OPRD1 | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist | AGONIST | https://conductscience.org/library/genes/4985 |
| OPRK1 | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist | AGONIST | https://conductscience.org/library/genes/4986 |
| OPRM1 | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist | AGONIST | https://conductscience.org/library/genes/4988 |
Source ChEMBL
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Chronic pain | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=HP_0012532 |
| Pain | Approval | ATC and TTD | 5 | 3 | https://conductscience.org/library/drugs?q=HP_0012531 |
| Low back pain | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0003419 |
| cancer pain | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0801084 |
| neuropathic pain | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0005762 |
Source Open Targets
Trials21
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02625181 | Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis | 27,034 | 2019-03-07 | oxymorphone | Its name | ClinicalTrials.gov | |
| NCT00955110 | Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin) | Phase 4 | 78 | 2011-07-14 | oxymorphone | Its name | ClinicalTrials.gov |
| NCT01210352 | Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects | Phase 3 | 61 | 2019-05-07 | oxymorphone | Its name | ClinicalTrials.gov |
| NCT00801398 | Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects. | Phase 3 | 58 | 2019-02-27 | oxymorphone | Its name | ClinicalTrials.gov |
| NCT02741076 | Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain | Phase 4 | 44 | 2019-11-06 | oxymorphone | Its name | ClinicalTrials.gov |
| NCT00930943 | Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning | Phase 4 | 30 | 2023-05-09 | oxymorphone | Its name | ClinicalTrials.gov |
| NCT00765856 | Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects | Phase 3 | 27 | 2020-12-16 | oxymorphone | Its name | ClinicalTrials.gov |
| NCT03389750 | A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists. | Phase 2 | 16 | 2023-09-07 | oxymorphone | Its name | ClinicalTrials.gov |
| NCT00580294 | A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation) | 12 | 2016-02-03 | oxymorphone | Its name | ClinicalTrials.gov | |
| NCT00226395 | Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain | Phase 3 | 320 | oxymorphone | Its name | ClinicalTrials.gov |
1 to 10 of 21
See all 21 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oxymorphone 40 mg With High-fat Meal vs Oxymorphone 40 mg Fasting: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT00930943 | Trial comparisons |
| Oxymorphone 40 mg With High-fat Meal vs Oxymorphone 40 mg Fasting: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT00930943 | Trial comparisons |
| Titration Period vs Maintenance Period: deaths from any cause | 0 of 27 | 0 of 24 | 51 | NCT00765856 | Trial comparisons |
| Titration Period vs Maintenance Period: serious adverse events | 0 of 27 | 3 of 24 | 51 | NCT00765856 | Trial comparisons |
Papers from its trials6
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials3
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Rapid Visual Information Processing | 1 | 1 | ConductCognition |
| Spatial Recognition Memory | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL963
GET https://conductscience.org/api/drugs/v1/CHEMBL963/trials?page=2